449 related articles for article (PubMed ID: 25804437)
1. Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.
Sanders KL; Fox BA; Bzik DJ
Cancer Immunol Res; 2015 Aug; 3(8):891-901. PubMed ID: 25804437
[TBL] [Abstract][Full Text] [Related]
2. Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.
Baird JR; Fox BA; Sanders KL; Lizotte PH; Cubillos-Ruiz JR; Scarlett UK; Rutkowski MR; Conejo-Garcia JR; Fiering S; Bzik DJ
Cancer Res; 2013 Jul; 73(13):3842-51. PubMed ID: 23704211
[TBL] [Abstract][Full Text] [Related]
3. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
[TBL] [Abstract][Full Text] [Related]
4. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
5. IL-15 prolongs the duration of CD8+ T cell-mediated immunity in mice infected with a vaccine strain of Toxoplasma gondii.
Khan IA; Casciotti L
J Immunol; 1999 Oct; 163(8):4503-9. PubMed ID: 10510393
[TBL] [Abstract][Full Text] [Related]
6. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.
Zhang Y; Velez-Delgado A; Mathew E; Li D; Mendez FM; Flannagan K; Rhim AD; Simeone DM; Beatty GL; Pasca di Magliano M
Gut; 2017 Jan; 66(1):124-136. PubMed ID: 27402485
[TBL] [Abstract][Full Text] [Related]
7. NK cells help to induce CD8(+)-T-cell immunity against Toxoplasma gondii in the absence of CD4(+) T cells.
Combe CL; Curiel TJ; Moretto MM; Khan IA
Infect Immun; 2005 Aug; 73(8):4913-21. PubMed ID: 16041005
[TBL] [Abstract][Full Text] [Related]
8. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
9. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.
Yan J; Tingey C; Lyde R; Gorham TC; Choo DK; Muthumani A; Myles D; Weiner LP; Kraynyak KA; Reuschel EL; Finkel TH; Kim JJ; Sardesai NY; Ugen KE; Muthumani K; Weiner DB
Cancer Gene Ther; 2014 Dec; 21(12):507-17. PubMed ID: 25394503
[TBL] [Abstract][Full Text] [Related]
10. Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines.
Fox BA; Sanders KL; Chen S; Bzik DJ
Trends Parasitol; 2013 Sep; 29(9):431-7. PubMed ID: 23928100
[TBL] [Abstract][Full Text] [Related]
11. DNA immunization with eukaryotic initiation factor-2α of Toxoplasma gondii induces protective immunity against acute and chronic toxoplasmosis in mice.
Chen J; Huang SY; Zhou DH; Li ZY; Petersen E; Song HQ; Zhu XQ
Vaccine; 2013 Dec; 31(52):6225-31. PubMed ID: 24183979
[TBL] [Abstract][Full Text] [Related]
12. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine.
Gazzinelli RT; Hakim FT; Hieny S; Shearer GM; Sher A
J Immunol; 1991 Jan; 146(1):286-92. PubMed ID: 1670604
[TBL] [Abstract][Full Text] [Related]
13. Toxoplasma gondii: protective immunity induced by rhoptry protein 9 (TgROP9) against acute toxoplasmosis.
Chen J; Zhou DH; Li ZY; Petersen E; Huang SY; Song HQ; Zhu XQ
Exp Parasitol; 2014 Apr; 139():42-8. PubMed ID: 24602875
[TBL] [Abstract][Full Text] [Related]
14. β-Adrenergic Signaling Impairs Antitumor CD8
Nissen MD; Sloan EK; Mattarollo SR
Cancer Immunol Res; 2018 Jan; 6(1):98-109. PubMed ID: 29146881
[TBL] [Abstract][Full Text] [Related]
15. Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment.
Wong JL; Obermajer N; Odunsi K; Edwards RP; Kalinski P
Cancer Immunol Res; 2016 Apr; 4(4):303-11. PubMed ID: 26817996
[TBL] [Abstract][Full Text] [Related]
16. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Cekic C; Day YJ; Sag D; Linden J
Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
[TBL] [Abstract][Full Text] [Related]
17. Fas Ligand Deficiency Impairs Tumor Immunity by Promoting an Accumulation of Monocytic Myeloid-Derived Suppressor Cells.
Peyvandi S; Buart S; Samah B; Vétizou M; Zhang Y; Durrieu L; Polrot M; Chouaib S; Benihoud K; Louache F; Karray S
Cancer Res; 2015 Oct; 75(20):4292-301. PubMed ID: 26359460
[TBL] [Abstract][Full Text] [Related]
18. The immunogenicity of dendritic cell-derived exosomes.
Quah BJ; O'Neill HC
Blood Cells Mol Dis; 2005; 35(2):94-110. PubMed ID: 15975838
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
20. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]